← Back to Search

MRI for Brain Tumor Detection After Radiation

N/A
Recruiting
Led By Ayal Aizer, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be age 18 years or older
Participants must have a histologically or cytologically confirmed solid malignancy of extracranial origin and radiographic evidence of at least one brain metastasis for which stereotactic radiation was utilized in the past
Must not have
Participants who have chronic kidney disease stage IV-V or end stage renal disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 3 months of study enrollment
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying whether an MRI can show if a brain tumor has come back after treatment with radiation.

Who is the study for?
This trial is for adults with confirmed extracranial solid malignancies and brain metastases previously treated with focused radiation. They must be planning neurosurgical resection as standard care, agree to use contraception, and be able to consent. Excluded are those with severe kidney disease, gadolinium allergy, pregnancy, breastfeeding or MRI contraindications.
What is being tested?
The study tests a specialized MRI technique to distinguish between tumor recurrence and radiation changes in the brain after stereotactic radiation therapy for brain metastases. Participants will undergo this imaging method before planned surgical removal of the lesion.
What are the potential side effects?
While MRIs are generally safe and non-invasive, potential side effects include discomfort from lying still during the procedure or reactions in those allergic to contrast agents used (gadolinium), though such individuals are excluded from this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have cancer that started outside the brain but now has spread to the brain, and I've had radiation for it.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have advanced chronic kidney disease or am in end stage renal failure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 3 months of study enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 3 months of study enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sensitivity
Secondary study objectives
Negative predictive value
Positive predictive value
Specificity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TRAMs IExperimental Treatment1 Intervention
* Magnetic resonance imaging (MRI)-based treatment response assessment maps (TRAMs) * Patients with an enlarging lesion in the site of a brain metastasis treated with stereotactic radiation for which neurosurgical resection is planned will undergo preoperative TRAMs
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI
2009
Completed Phase 2
~2810

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,108 Previous Clinical Trials
357,136 Total Patients Enrolled
Ayal Aizer, MDPrincipal Investigator - Dana-Farber Cancer Institute
Brigham & Women's Hospital, Brigham and Women's Physicians Organization, Dana-Farber Cancer Institute
Yale University School Of Medicine (Medical School)

Media Library

MRI Clinical Trial Eligibility Overview. Trial Name: NCT04033497 — N/A
Brain Tumor Research Study Groups: TRAMs I
Brain Tumor Clinical Trial 2023: MRI Highlights & Side Effects. Trial Name: NCT04033497 — N/A
MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT04033497 — N/A
~33 spots leftby Jul 2027